AdAlta: Developing breakthrough treatments for fibrotic diseases




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: AdAlta: Developing breakthrough treatments for fibrotic diseases
Released on: November 29, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    AdAlta Limited is a drug discovery and development company focused on using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases.
  • Summary
  • Participants
  • Company
AdAlta Limited is a drug discovery and development company focused on using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases. Fintan Walton, CEO of PharmaVentures talks with Sam Cobb, CEO of AdAlta
Sam Cobb, CEO, AdAlta
AdAlta Limited is a drug discovery and development company focused on using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases. i-bodies are a human analogue of the antigen binding domain of the shark antibody; they combine the high target specificity and affinity advantages of antibodies with the beneficial features of small molecule drugs. The Company’s lead i-body candidate, AD-114, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. AdAlta intends to continue further discovery and development activities directed towards other disease targets for in-house development or partnering. The Company is led by an experienced management team and Board and is supported by a world class scientific advisory board. Both AdAlta’s i-body technology platform and lead i-body drug candidate, AD-114, are protected by a strong portfolio of worldwide granted patents and pending applications. AdAlta is headquartered in Melbourne, Australia